Compugen to Present at Needham Healthcare Conference Amid Key Clinical Milestones
Event summary
- Compugen to present at 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, 8:45-9:25 AM ET.
- Company has two Fc-reduced TIGIT-targeting programs: COM902 (Phase 1) and rilvegostomig (Phase 3 via AstraZeneca).
- Additional Phase 1 programs include COM701 (anti-PVRIG) and GS-0321 (anti-IL-18, licensed to Gilead).
- Shares listed on NASDAQ and Tel Aviv Stock Exchange under ticker CGEN.
The big picture
Compugen's presentation comes as cancer immunotherapy remains a high-priority sector for biotech investors, with TIGIT-targeting therapies gaining particular attention. The company's AI/ML-powered discovery platform positions it as a potential consolidator in the computational drug discovery space, though its ability to translate early-stage programs into commercial successes will be critical for long-term growth.
What we're watching
- Clinical Progress
- How COM902's Phase 1 results will impact Compugen's valuation and AstraZeneca's Phase 3 rilvegostomig program.
- Partnership Dynamics
- Whether Gilead will advance GS-0321 (formerly COM503) through later-stage development.
- Pipeline Expansion
- The pace at which Compugen's early-stage immuno-oncology programs move toward clinical stages.
Related topics